Heparin Binding Protein ELISA

Enzyme immunoassay for the quantitative determination of Heparin Binding Protein in human plasma. Heparin Binding Protein is a new marker that has demonstrated utility in identifying patients at risk of developing severe sepsis. Heparin Binding Protein, also known as CAP37 and azurocidin, is synthesised in neutrophils. Once released from activated neutrophils, it induces a rearrangement of the endothelial cell cytoskeleton, resulting in increased permeability of the endothelium. At the site of infection, HBP is responsible for the recruitment and activation of monocytes and other inflammatory mediators. It is also internalised by monocytes to prolong survival and enhance cytokine production. HBP therefore directly contributes to the maintenance and progression of inflammation. A publication in 2009 demonstrated that in febrile patients presenting to the Emergency Department (ED), there is a close correlation between increased plasma HBP levels and the development of severe sepsis with hypotension or shock. In this prospective study of 233 febrile adult patients with suspected sepsis, Heparin Binding Protein was shown to be the best predictor of severe sepsis with Receiver-operating characteristic (ROC) plot showing an Area Under Curve (AUC) of 0.95, exceeding that of Procalcitonin, IL-6 and Lactate:

Distributed by IBL International